COVID-19 Vaccine of US Company Novavax Shows 89.3% Efficacy in Phase 3 Trial in UK

Jan 29, 2021 | EARNINGS

MOSCOW (Sputnik) – A coronavirus vaccine developed by the US-based Novavax company has demonstrated an 89.3-percent efficacy during phase 3 trials conducted in the United Kingdom, the company said in a statement.

Read More

Pin It on Pinterest